Skip to main content

Table 3 Drugs with significant enrichment to diurnal signature in the Connectivity Map

From: Diurnal variation of the human adipose transcriptome and the link to metabolic disease

rank drug mean n p-value
1 sirolimus 0.68 10 0
2 LY-294002 0.54 17 0
3 wortmannin 0.62 8 0.0001
4 trichostatin A 0.48 12 0.0012
5 resveratrol 0.61 5 0.0026
6 5182598 -0.78 2 0.0043
7 estradiol -0.39 10 0.0079
8 iloprost -0.71 3 0.0105
9 tacrolimus -0.56 3 0.0153
10 arachidonyltrifluoromethane -0.75 2 0.02
11 deferoxamine 0.49 3 0.0292
12 fludrocortisone -0.60 2 0.0429
13 quercetin -0.53 2 0.0607
14 TTNPB -0.57 2 0.0645
15 vorinostat 0.53 2 0.0734
16 fulvestrant 0.39 7 0.0858
17 raloxifene -0.15 3 0.0876
18 rottlerin 0.43 3 0.0945
  1. The drugs with significant connectivity to the diurnal signature are ranked in the order of significance of the connectivity score as judged by the permutation p-value (column labeled "p-value"). Significance cut-off was set at pvalue = 0.1. The permutation p-value estimates the likelihood that the enrichment of a given set of post-dose gene expression changes (instances) by a given drug, relative to all available post-dose changes in the CMAP database (for all drugs) would be observed by random chance. Mean: the arithmetic mean of the connectivity scores for the post-dose changes by the given drug; N: the number of instances of a given drug in CMAP database[23].